Nektar Therapeutics (NKTR) Short-term Investments (2010 - 2026)

Nektar Therapeutics' Short-term Investments history runs 17 years deep, the most recent figure standing at $419.0 million for Q1 2026.

• In Q1 2026, Short-term Investments rose 133.13% year-over-year to $419.0 million; the TTM figure through Mar 2026 stood at $419.0 million (up 133.13% YoY), while the FY2025 annual figure was $230.6 million, up 9.32% from the prior year.
• Short-term Investments was $419.0 million for Q1 2026 at Nektar Therapeutics, up from $230.6 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $599.0 million in Q1 2022 to a low of $132.9 million in Q2 2025.
• Historically, Short-term Investments has averaged $318.4 million across 5 years, with a median of $268.3 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Short-term Investments tumbled 49.18% in 2022, then jumped 133.13% in 2026.
• A 5-year view of Short-term Investments shows it stood at $416.8 million in 2022, then plunged by 35.61% to $268.3 million in 2023, then slipped by 21.38% to $211.0 million in 2024, then advanced by 9.32% to $230.6 million in 2025, then surged by 81.68% to $419.0 million in 2026.
• The last three Short-term Investments figures came in at $419.0 million (Q1 2026), $230.6 million (Q4 2025), and $229.2 million (Q3 2025), per Business Quant data.